EPAS1 and metabolic dysfunction-associated steatohepatitis: Notably, we found that the pharmacological activation of macrophage HIF-2α by FG-4592, a HIF prolyl hydroxylase inhibitor that is approved for the treatment of anaemia in China, had preventive effects on NASH in mice.